Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus
Background Exenatide is a GLP-1R agonist that often exhibits considerable interindividual variability in therapeutic efficacy. However, there is no evidence about the impact of genetic variants in the PPARD on the therapeutic efficacy of exenatide. This research was aimed to explore the influence of...
Saved in:
Published in | Frontiers in endocrinology (Lausanne) Vol. 13; p. 949990 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Frontiers Media S.A
16.08.2022
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background
Exenatide is a GLP-1R agonist that often exhibits considerable interindividual variability in therapeutic efficacy. However, there is no evidence about the impact of genetic variants in the
PPARD
on the therapeutic efficacy of exenatide. This research was aimed to explore the influence of
PPARD
gene polymorphism on the therapeutic effect of exenatide, and to identify the potential mechanism futher.
Methods
A total of 300 patients with T2DM and 200 control subjects were enrolled to identify
PPARD
rs2016520 and rs3777744 genotypes. A prospective clinical study was used to collect clinical indicators and peripheral blood of T2DM patients treated with exenatide monotherapy for 6 months. The SNaPshot method was used to identify
PPARD
rs2016520 and rs3777744 genotypes, and then we performed correlation analysis between
PPARD
gene variants and the efficacy of exenatide, and conducted multiple linear regression analysis of factors affecting the therapeutic effect of exenatide. HepG2 cells were incubated with exenatide in the absence or presence of a PPARδ agonist or the siPPARδ plasmid, after which the levels of GLP-1R and the ratio of glucose uptake were determined.
Results
After 6 months exenatide monotherapy, we observed that homeostasis model assessment for insulin resistance (HOMA-IR) levels of the subjects with at least one C allele of the
PPARD
rs2016520 were significantly lower than those with the TT genotype, which suggested that the
PPARD
rs2016520 TT genotype conferred the poor exenatide response through a reduction of insulin resistance, as measured by HOMA-IR. The carriers of G alleles at rs3777744 exhibited higher levels of in waist to hip ratio (WHR), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) and HOMA-IR compared to individuals with the AA genotype following 6 months of exenatide treatment, potentially accounting for the lower failure rate of exenatide therapy among the AA homozygotes. In an insulin resistant HepG2 cell model, the PPARδ agonists enhanced exenatide efficacy on insulin resistance, with the expression of GLP-1R being up-regulated markedly.
Conclusion
These data suggest that the
PPARD
rs2016520 and rs3777744 polymorphisms are associated with exenatide monotherapy efficacy, due to the pivotal role of PPARδ in regulating insulin resistance through affecting the expression of GLP-1R. This study was registered in the Chinese Clinical Trial Register (No. ChiCTR-CCC13003536). |
---|---|
AbstractList | BackgroundExenatide is a GLP-1R agonist that often exhibits considerable interindividual variability in therapeutic efficacy. However, there is no evidence about the impact of genetic variants in the PPARD on the therapeutic efficacy of exenatide. This research was aimed to explore the influence of PPARD gene polymorphism on the therapeutic effect of exenatide, and to identify the potential mechanism futher. MethodsA total of 300 patients with T2DM and 200 control subjects were enrolled to identify PPARD rs2016520 and rs3777744 genotypes. A prospective clinical study was used to collect clinical indicators and peripheral blood of T2DM patients treated with exenatide monotherapy for 6 months. The SNaPshot method was used to identify PPARD rs2016520 and rs3777744 genotypes, and then we performed correlation analysis between PPARD gene variants and the efficacy of exenatide, and conducted multiple linear regression analysis of factors affecting the therapeutic effect of exenatide. HepG2 cells were incubated with exenatide in the absence or presence of a PPARδ agonist or the siPPARδ plasmid, after which the levels of GLP-1R and the ratio of glucose uptake were determined. ResultsAfter 6 months exenatide monotherapy, we observed that homeostasis model assessment for insulin resistance (HOMA-IR) levels of the subjects with at least one C allele of the PPARD rs2016520 were significantly lower than those with the TT genotype, which suggested that the PPARD rs2016520 TT genotype conferred the poor exenatide response through a reduction of insulin resistance, as measured by HOMA-IR. The carriers of G alleles at rs3777744 exhibited higher levels of in waist to hip ratio (WHR), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) and HOMA-IR compared to individuals with the AA genotype following 6 months of exenatide treatment, potentially accounting for the lower failure rate of exenatide therapy among the AA homozygotes. In an insulin resistant HepG2 cell model, the PPARδ agonists enhanced exenatide efficacy on insulin resistance, with the expression of GLP-1R being up-regulated markedly. ConclusionThese data suggest that the PPARD rs2016520 and rs3777744 polymorphisms are associated with exenatide monotherapy efficacy, due to the pivotal role of PPARδ in regulating insulin resistance through affecting the expression of GLP-1R. This study was registered in the Chinese Clinical Trial Register (No. ChiCTR-CCC13003536). Background Exenatide is a GLP-1R agonist that often exhibits considerable interindividual variability in therapeutic efficacy. However, there is no evidence about the impact of genetic variants in the PPARD on the therapeutic efficacy of exenatide. This research was aimed to explore the influence of PPARD gene polymorphism on the therapeutic effect of exenatide, and to identify the potential mechanism futher. Methods A total of 300 patients with T2DM and 200 control subjects were enrolled to identify PPARD rs2016520 and rs3777744 genotypes. A prospective clinical study was used to collect clinical indicators and peripheral blood of T2DM patients treated with exenatide monotherapy for 6 months. The SNaPshot method was used to identify PPARD rs2016520 and rs3777744 genotypes, and then we performed correlation analysis between PPARD gene variants and the efficacy of exenatide, and conducted multiple linear regression analysis of factors affecting the therapeutic effect of exenatide. HepG2 cells were incubated with exenatide in the absence or presence of a PPARδ agonist or the siPPARδ plasmid, after which the levels of GLP-1R and the ratio of glucose uptake were determined. Results After 6 months exenatide monotherapy, we observed that homeostasis model assessment for insulin resistance (HOMA-IR) levels of the subjects with at least one C allele of the PPARD rs2016520 were significantly lower than those with the TT genotype, which suggested that the PPARD rs2016520 TT genotype conferred the poor exenatide response through a reduction of insulin resistance, as measured by HOMA-IR. The carriers of G alleles at rs3777744 exhibited higher levels of in waist to hip ratio (WHR), fasting plasma glucose (FPG), hemoglobin A1c (HbA1c) and HOMA-IR compared to individuals with the AA genotype following 6 months of exenatide treatment, potentially accounting for the lower failure rate of exenatide therapy among the AA homozygotes. In an insulin resistant HepG2 cell model, the PPARδ agonists enhanced exenatide efficacy on insulin resistance, with the expression of GLP-1R being up-regulated markedly. Conclusion These data suggest that the PPARD rs2016520 and rs3777744 polymorphisms are associated with exenatide monotherapy efficacy, due to the pivotal role of PPARδ in regulating insulin resistance through affecting the expression of GLP-1R. This study was registered in the Chinese Clinical Trial Register (No. ChiCTR-CCC13003536). |
Author | Lu, Qian Xu, Ke Yu, Yanan Ling, Hongwei Yin, Xiaoxing Li, Na Song, Jinfang Hu, Ruonan Wang, Tao Yang, Tingting |
AuthorAffiliation | 1 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University , Xuzhou , China 3 Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University , Xuzhou , China 4 Department of Pharmacy, Affiliated Hospital of Xuzhou Medical University , Xuzhou , China 2 Department of Pharmacy, Affiliated Hospital of Jiangnan University , Wuxi , China |
AuthorAffiliation_xml | – name: 2 Department of Pharmacy, Affiliated Hospital of Jiangnan University , Wuxi , China – name: 3 Department of Endocrinology, Affiliated Hospital of Xuzhou Medical University , Xuzhou , China – name: 1 Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University , Xuzhou , China – name: 4 Department of Pharmacy, Affiliated Hospital of Xuzhou Medical University , Xuzhou , China |
Author_xml | – sequence: 1 givenname: Jinfang surname: Song fullname: Song, Jinfang – sequence: 2 givenname: Na surname: Li fullname: Li, Na – sequence: 3 givenname: Ruonan surname: Hu fullname: Hu, Ruonan – sequence: 4 givenname: Yanan surname: Yu fullname: Yu, Yanan – sequence: 5 givenname: Ke surname: Xu fullname: Xu, Ke – sequence: 6 givenname: Hongwei surname: Ling fullname: Ling, Hongwei – sequence: 7 givenname: Qian surname: Lu fullname: Lu, Qian – sequence: 8 givenname: Tingting surname: Yang fullname: Yang, Tingting – sequence: 9 givenname: Tao surname: Wang fullname: Wang, Tao – sequence: 10 givenname: Xiaoxing surname: Yin fullname: Yin, Xiaoxing |
BookMark | eNpVkl1rFTEQhhep2Fr7A7zLpTfnmK_Nx41Qaq2FgkX0OmSTyTkpe5I1yanWX9_dniI2EDK8M_OEGd633VHKCbruPcFrxpT-GCD5vKaY0rXmWmv8qjshQvAVZZoe_Rcfd2e13uH5cEy0Vm-6YyZwT5iSJ93fyxDAtYpyQLe3598_ow0kQPe2RJsWOaG2heUWO8G-RYcK1CmnChW1jOAPJNuiBxQTctuYoAKaZgWW7t-xbVF7mABR5KMdoM1dOxjH2Pb1Xfc62LHC2fN72v38cvnj4uvq5tvV9cX5zcpxTtuK9ZyQoddEKsXsoJQV2CoxgA5cBi-Ait5RHcBzrq31YtBaEuZ7QRjTUrLT7vrA9dnemanEnS0PJttonoRcNsaWebARDHZS9targTjPWe-UlU4EDL3yzgO3M-vTgTXthx14N09Z7PgC-jKT4tZs8r3RnHKh9Az48Awo-dceajO7WN28EZsg76uhEmvJhFJkLiWHUldyrQXCv28INosFzJMFzGIBc7AAewRHB6fn |
CitedBy_id | crossref_primary_10_26442_00403660_2023_03_202150 crossref_primary_10_17116_profmed20232612195 crossref_primary_10_3390_biom13121791 crossref_primary_10_3390_nu14245378 |
Cites_doi | 10.2337/dc21-S001. 10.1007/s00125-009-1344-5 10.1007/s00210-017-1445-5 10.1016/j.gene.2016.02.035 10.1194/jlr.M046037 10.1007/s00125-007-0753-6 10.1038/s41401-020-0450-2 10.1056/NEJMcibr1607950 10.1152/ajpendo.00309.2012 10.1111/joim.12293 10.1126/science.1138239 10.1111/jcpt.13134 10.1042/BSR20181510 10.1002/dmrr.3109 10.1155/2012/680684 10.1002/psb.1450 10.1186/s12933-018-0762-4 10.1002/ptr.5254 10.1038/srep37293 10.3390/cells9051133 10.1007/s40265-013-0172-6 10.1111/cge.12817 10.1136/bmj.321.7258.405 10.2217/fca-2017-0019 10.2217/pgs-2017-0195 10.1016/S2213-8587(18)30052-4 10.1016/j.metabol.2020.154342 10.1172/JCI42127 10.1111/dom.13129 10.1111/j.1464-5491.2006.02001.x 10.1007/s00125-009-1307-x 10.1016/S0092-8674(03)00269-1 10.1371/journal.pone.0163668 10.1038/nature15393 10.2337/diabetes.53.3.847 10.1210/jc.2009-0392 10.3390/genes11070776 |
ContentType | Journal Article |
Copyright | Copyright © 2022 Song, Li, Hu, Yu, Xu, Ling, Lu, Yang, Wang and Yin 2022 Song, Li, Hu, Yu, Xu, Ling, Lu, Yang, Wang and Yin |
Copyright_xml | – notice: Copyright © 2022 Song, Li, Hu, Yu, Xu, Ling, Lu, Yang, Wang and Yin 2022 Song, Li, Hu, Yu, Xu, Ling, Lu, Yang, Wang and Yin |
DBID | AAYXX CITATION 7X8 5PM DOA |
DOI | 10.3389/fendo.2022.949990 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) Open Access: DOAJ - Directory of Open Access Journals |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1664-2392 |
EndPage | 949990 |
ExternalDocumentID | oai_doaj_org_article_0c775ad8b1cd435c8a7c6f0e58dcde4a 10_3389_fendo_2022_949990 |
GrantInformation_xml | – fundername: ; |
GroupedDBID | 53G 5VS 9T4 AAFWJ AAKDD AAYXX ACGFO ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK EMOBN GROUPED_DOAJ GX1 HYE IAO IEA IHR IHW KQ8 M48 M~E OK1 PGMZT RPM 7X8 ITC 5PM |
ID | FETCH-LOGICAL-c442t-35411b5917883ab88a60a86be9f47fd6e265c29fed449aad6b99713d561339773 |
IEDL.DBID | RPM |
ISSN | 1664-2392 |
IngestDate | Fri Oct 04 13:06:49 EDT 2024 Tue Sep 17 21:27:19 EDT 2024 Fri Aug 16 12:12:33 EDT 2024 Thu Sep 26 18:09:18 EDT 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Language | English |
License | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c442t-35411b5917883ab88a60a86be9f47fd6e265c29fed449aad6b99713d561339773 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Diabetes: Molecular Mechanisms, a section of the journal Frontiers in Endocrinology Edited by: Jian-Quan Luo, Central South University, China Reviewed by: Qian Ren, Nanjing Normal University, China; Gopal L. Khatik, National Institute of Pharmaceutical Education and Research, India |
OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9424689/ |
PMID | 36051387 |
PQID | 2709736881 |
PQPubID | 23479 |
PageCount | 1 |
ParticipantIDs | doaj_primary_oai_doaj_org_article_0c775ad8b1cd435c8a7c6f0e58dcde4a pubmedcentral_primary_oai_pubmedcentral_nih_gov_9424689 proquest_miscellaneous_2709736881 crossref_primary_10_3389_fendo_2022_949990 |
PublicationCentury | 2000 |
PublicationDate | 2022-08-16 |
PublicationDateYYYYMMDD | 2022-08-16 |
PublicationDate_xml | – month: 08 year: 2022 text: 2022-08-16 day: 16 |
PublicationDecade | 2020 |
PublicationTitle | Frontiers in endocrinology (Lausanne) |
PublicationYear | 2022 |
Publisher | Frontiers Media S.A |
Publisher_xml | – name: Frontiers Media S.A |
References | Carrillo-Venzor (B8) 2020; 11 (B25) 2016; 27 Zhang (B35) 2019; 39 Shin (B5) 2004; 53 Han (B11) 2017; 13 Bojic (B12) 2014; 55 McCormack (B15) 2014; 74 Ordelheide (B21) 2018; 19 Tang (B6) 2016; 585 Gloyn (B22) 2018; 6 Pilgaard (B18) 2009; 52 Xu (B16) 2015; 277 (B1) 2021; 44 Zhang (B29) 2018; 391 Zarei (B34) 2021; 114 Wang (B17) 2020; 45 Kong (B23) 2017; 91 Schäfer (B20) 2009; 52 Greene (B13) 2012; 303 Iglesias (B10) 2012; 122 Mannino (B2) 2019; 35 Auton (B31) 2015; 526 Stratton (B26) 2000; 321 Zhou (B27) 2016; 6 Zhu (B30) 2015; 29 Hu (B7) 2006; 23 Nauck (B14) 2018 Du (B28) 2021; 42 Komar (B37) 2007; 315 Persaud (B3) 2016; 375 Schäfer (B19) 2007; 50 Li (B24) 2016; 11 Wagner (B4) 2020; 9 Wang (B32) 2003; 113 Burch (B33) 2009; 94 Ormazabal (B36) 2018; 17 Cao (B9) 2012; 2012 |
References_xml | – volume: 44 start-page: S7 year: 2021 ident: B1 article-title: Improving care and promoting health in populations: Standards of medical care in diabetes-2021 publication-title: Diabetes Care doi: 10.2337/dc21-S001. – volume: 52 year: 2009 ident: B20 article-title: A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion publication-title: Diabetologia doi: 10.1007/s00125-009-1344-5 contributor: fullname: Schäfer – volume: 391 year: 2018 ident: B29 article-title: Sarsasapogenin suppresses aβ overproduction induced by high glucose in HT-22 cells publication-title: Naunyn Schmiedebergs Arch Pharmacol doi: 10.1007/s00210-017-1445-5 contributor: fullname: Zhang – volume: 585 year: 2016 ident: B6 article-title: PPARD rs2016520 polymorphism is associated with metabolic traits in a large population of Chinese adults publication-title: Gene doi: 10.1016/j.gene.2016.02.035 contributor: fullname: Tang – volume: 55 year: 2014 ident: B12 article-title: PPARδ activation attenuates hepatic steatosis in ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity publication-title: J Lipid Res doi: 10.1194/jlr.M046037 contributor: fullname: Bojic – volume: 50 year: 2007 ident: B19 article-title: Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms publication-title: Diabetologia doi: 10.1007/s00125-007-0753-6 contributor: fullname: Schäfer – volume: 42 year: 2021 ident: B28 article-title: Sirt1 inhibits renal tubular cell epithelial-mesenchymal transition through YY1 deacetylation in diabetic nephropathy publication-title: Acta Pharmacol Sin doi: 10.1038/s41401-020-0450-2 contributor: fullname: Du – volume: 375 year: 2016 ident: B3 article-title: A wake-up call for type 2 diabetes publication-title: N Engl J Med doi: 10.1056/NEJMcibr1607950 contributor: fullname: Persaud – volume: 303 year: 2012 ident: B13 article-title: Regulators of blood lipids and lipoproteins? PPARδ and AMPK, induced by exercise, are correlated with lipids and lipoproteins in overweight/obese men and women publication-title: Am J Physiol Endocrinol Metab doi: 10.1152/ajpendo.00309.2012 contributor: fullname: Greene – volume: 277 year: 2015 ident: B16 article-title: Comparison of the effects on glycaemic control and β-cell function in newly diagnosed type 2 diabetes patients of treatment with exenatide, insulin or pioglitazone: A multicentre randomized parallel-group trial (the CONFIDENCE study) publication-title: J Intern Med doi: 10.1111/joim.12293 contributor: fullname: Xu – volume: 315 year: 2007 ident: B37 article-title: Genetics. SNPs, silent but not invisible publication-title: Science doi: 10.1126/science.1138239 contributor: fullname: Komar – volume: 45 year: 2020 ident: B17 article-title: Predictive factors associated with glycaemic response to exenatide in Chinese patients with type 2 diabetes mellitus publication-title: J Clin Pharm Ther doi: 10.1111/jcpt.13134 contributor: fullname: Wang – volume: 39 start-page: BSR20181510 year: 2019 ident: B35 article-title: The association between peroxisome proliferator-activated receptor Δ rs3777744, rs3798343, and rs6922548 and coronary artery disease publication-title: Biosci Rep doi: 10.1042/BSR20181510 contributor: fullname: Zhang – volume: 35 year: 2019 ident: B2 article-title: Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine publication-title: Diabetes Metab Res Rev doi: 10.1002/dmrr.3109 contributor: fullname: Mannino – volume: 2012 start-page: 680684 year: 2012 ident: B9 article-title: PPARδ activation rescues pancreatic β-cell line INS-1E from palmitate-induced endoplasmic reticulum stress through enhanced fatty acid oxidation publication-title: PPAR Res doi: 10.1155/2012/680684 contributor: fullname: Cao – volume: 27 year: 2016 ident: B25 article-title: NICE guidance on managing type 2 diabetes in adults publication-title: Prescriber doi: 10.1002/psb.1450 – volume: 17 start-page: 122 year: 2018 ident: B36 article-title: Association between insulin resistance and the development of cardiovascular disease publication-title: Cardiovasc Diabetol doi: 10.1186/s12933-018-0762-4 contributor: fullname: Ormazabal – volume: 29 start-page: 295 year: 2015 ident: B30 article-title: Mangiferin attenuates renal fibrosis through down-regulation of osteopontin in diabetic rats publication-title: Phytother Res doi: 10.1002/ptr.5254 contributor: fullname: Zhu – volume: 6 start-page: 37293 year: 2016 ident: B27 article-title: A variation in KCNQ1 gene is associated with repaglinide efficacy on insulin resistance in Chinese type 2 diabetes mellitus patients publication-title: Sci Rep doi: 10.1038/srep37293 contributor: fullname: Zhou – volume: 9 start-page: 1133 year: 2020 ident: B4 article-title: PPAR beta/delta and the hallmarks of cancer publication-title: Cells. doi: 10.3390/cells9051133 contributor: fullname: Wagner – volume: 74 year: 2014 ident: B15 article-title: Exenatide twice daily: A review of its use in the management of patients with type 2 diabetes mellitus publication-title: Drugs doi: 10.1007/s40265-013-0172-6 contributor: fullname: McCormack – volume: 91 year: 2017 ident: B23 article-title: Association of a type 2 diabetes genetic risk score with insulin secretion modulated by insulin sensitivity among Chinese Hans publication-title: Clin Genet doi: 10.1111/cge.12817 contributor: fullname: Kong – volume: 321 year: 2000 ident: B26 article-title: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study publication-title: BMJ doi: 10.1136/bmj.321.7258.405 contributor: fullname: Stratton – volume: 13 year: 2017 ident: B11 article-title: PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ publication-title: Future Cardiol doi: 10.2217/fca-2017-0019 contributor: fullname: Han – volume: 19 year: 2018 ident: B21 article-title: Pharmacogenetics of oral antidiabetic therapy publication-title: Pharmacogenomics doi: 10.2217/pgs-2017-0195 contributor: fullname: Ordelheide – volume: 6 start-page: 891 year: 2018 ident: B22 article-title: Precision medicine in the management of type 2 diabetes publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(18)30052-4 contributor: fullname: Gloyn – volume: 114 start-page: 154342 year: 2021 ident: B34 article-title: Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease publication-title: Metabolism doi: 10.1016/j.metabol.2020.154342 contributor: fullname: Zarei – volume: 122 year: 2012 ident: B10 article-title: PPARβ/δ affects pancreatic β cell mass and insulin secretion in mice publication-title: J Clin Invest doi: 10.1172/JCI42127 contributor: fullname: Iglesias – start-page: 5 year: 2018 ident: B14 article-title: Incretin hormones: Their role in health and disease publication-title: Diabetes Obes Metab doi: 10.1111/dom.13129 contributor: fullname: Nauck – volume: 23 year: 2006 ident: B7 article-title: Peroxisome proliferator-activated receptor (PPAR) delta genetic polymorphism and its association with insulin resistance index and fasting plasma glucose concentrations in Chinese subjects publication-title: Diabetes Med doi: 10.1111/j.1464-5491.2006.02001.x contributor: fullname: Hu – volume: 52 year: 2009 ident: B18 article-title: The T allele of rs7903146 TCF7L2 is associated with impaired insulinotropic action of incretin hormones, reduced 24 h profiles of plasma insulin and glucagon, and increased hepatic glucose production in young healthy men publication-title: Diabetologia doi: 10.1007/s00125-009-1307-x contributor: fullname: Pilgaard – volume: 113 year: 2003 ident: B32 article-title: Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity publication-title: Cell doi: 10.1016/S0092-8674(03)00269-1 contributor: fullname: Wang – volume: 11 year: 2016 ident: B24 article-title: A population-based study of four genes associated with heroin addiction in han Chinese publication-title: PloS One doi: 10.1371/journal.pone.0163668 contributor: fullname: Li – volume: 526 start-page: 68 year: 2015 ident: B31 article-title: A global reference for human genetic variation publication-title: Nature doi: 10.1038/nature15393 contributor: fullname: Auton – volume: 53 year: 2004 ident: B5 article-title: Genetic polymorphisms in peroxisome proliferator-activated receptor delta associated with obesity publication-title: Diabetes doi: 10.2337/diabetes.53.3.847 contributor: fullname: Shin – volume: 94 year: 2009 ident: B33 article-title: A single nucleotide polymorphism on exon-4 of the gene encoding PPARdelta is associated with reduced height in adults and children publication-title: J Clin Endocrinol Metab doi: 10.1210/jc.2009-0392 contributor: fullname: Burch – volume: 11 start-page: 776 year: 2020 ident: B8 article-title: Pro12Ala PPAR-γ2 and +294T/C PPAR-δ polymorphisms and association with metabolic traits in teenagers from northern Mexico publication-title: Genes (Basel) doi: 10.3390/genes11070776 contributor: fullname: Carrillo-Venzor |
SSID | ssj0000401998 |
Score | 2.3539615 |
Snippet | Background
Exenatide is a GLP-1R agonist that often exhibits considerable interindividual variability in therapeutic efficacy. However, there is no evidence... BackgroundExenatide is a GLP-1R agonist that often exhibits considerable interindividual variability in therapeutic efficacy. However, there is no evidence... |
SourceID | doaj pubmedcentral proquest crossref |
SourceType | Open Website Open Access Repository Aggregation Database |
StartPage | 949990 |
SubjectTerms | Endocrinology exenatide genetic variant insulin resistance PPARD gene type 2 diabetes mellitus |
SummonAdditionalLinks | – databaseName: Open Access: DOAJ - Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Pi9UwEA6yB_Ei_sTnj2UET0LdJi9Jk-O67rIIyiIu7C2kzQT3YLts-0T8651p-6Q9edlrW2iab5qZb2byRYh3SH4UMesiSZ8KHY0vfJRN4VFnrMhHuTx2-X6155f685W5Whz1xT1hkzzwNHFHZVNVJiZXyyaRa29crBqbSzQuNQn1FBpJsyBT4xpMtIGIxFTGJBbmjzK2iTf7KfWB9Vh4DV44olGvfxVkrlskFz7n7JF4OAeLcDwN8rG4h-0Tcf_LXA5_Kv5M2sM9dBkuLo6_fQIyB4RfxH-5vQW6Fii-g8UeK7idemKxh6ED_I2cDEwI1y1wUyX2CLPSag-cogVO0YKCfYoWfrKA57Drn4nLs9PvJ-fFfJhC0WithmJrtJS1IXbm3DbWzkVbRmdr9FlXOVlU1jTKZ0xa-xiTrb0nApuYYHCQuH0uDtquxRcCKkVAqLqkyNHrGk2ULPnjy6QdEcgybcT7_cyGm0kzIxDXYBjCCENgGMIEw0Z85Ln_9yDLXY8XyAjCbAThf0awEW_3yAX6PbjmEVvsdn1QFesRWefkRlQrSFdvXN9pr3-MQtteK22df3kXQ3wlHvBXczpa2tfiYLjd4RuKZ4b6cDTdv2xh95g priority: 102 providerName: Directory of Open Access Journals – databaseName: Scholars Portal Open Access Journals dbid: M48 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1da9VAEF1KBfFF_MTrRxnBJyE1u3ez2X0QadVShEoRL_Rt2WRntaCJ3uRK21_vTJIrDfTB1yRsyMxu5pzZ2TNCvEKKo4hJZ1G6mOlQuMwFWWcOdcKSYpRNQ5XvZ3O80p_OirMdsW1vNRmwu5HacT-p1frH_sXvy3e04N8y46R4-yZhE_kcn1L7LLXiiMHfUnqpecKfTGh_-DETl3BDd1xpjM4UQYNxn_PmUWaRahD0n6HQeQ3ltaB0dE_cndAkHIzuvy92sHkgbp9M--UPxdUoTtxBm-D09ODLB6D5gvCHCDLXv0DbAAFAuHYIC9Zj0Sx20LeAF8jZwohw3gBXXWKHMEmxdsA5XOAcLijY5nDhJyt89pvukVgdffz6_jibui1ktdaqz5aFlrIqiL5ZuwyVtcHkwZoKXdJligaVKWrlEkatXQjRVM4Rw43MQBhFLh-L3aZt8ImAkqxfqConaOl0hUWQrAnk8qgtMcw8LsTrrWX9r1FUwxMZYTf4wQ2e3eBHNyzEIdv-34Oshz1caNff_LS8fF6XZRGirWQd6d21DWVtUo6FjXVEHRbi5dZzntYPb4qEBttN51XJgkXGWrkQ5cylszfO7zTn3wclbqeVNtY9_Y_Rn4k7_FGcjpbmudjt1xt8QXimr_aGWfoXH9X1Vw priority: 102 providerName: Scholars Portal |
Title | Effects of PPARD gene variants on the therapeutic responses to exenatide in chinese patients with type 2 diabetes mellitus |
URI | https://search.proquest.com/docview/2709736881 https://pubmed.ncbi.nlm.nih.gov/PMC9424689 https://doaj.org/article/0c775ad8b1cd435c8a7c6f0e58dcde4a |
Volume | 13 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Li9swEBa7eyi9lD5p-lhU6KngxJJlWTput90uhZRQupCbkaVxG2jsJXaWpb--M7JdkmsvOviBbM3YM9_o0yfG3gPGUYBaJUHYkCiX28Q64RMLqoYCY5SpI8v3m76-UV_X-fqE5dNamEja99Vm3vzezpvNr8itvN36xcQTW6yWl1ZJpY1dnLLTIssOIHr8_SJiQAwxzGAiALOLGppA6_yknJMUi6Xd3zJM40VGRLqDcBRV-49SzWOi5EHkuXrMHo0pI78YHu0JO4HmKXuwHCfFn7E_gwJxx9uar1YX3z9xdArgd4iCieTC24ZjlscPVlrx3cCMhY73LYd7oJJgAL5pOFEroQM-6q12nAq1nAq1XPKpUMu3JOPZ77vn7Obq84_L62TcUiHxSsk-yXIlRJUjRjMmc5UxTqfO6ApsrYo6aJA699LWEJSyzgVdWYswNhDMoFQxe8HOmraBl4wXEjMtWaWYP1pVQe4ECf_YNCiDMDINM_ZhGtnydlDOKBFxkEXKaJGSLFIOFpmxjzT2_y4k0et4oN39LEfTl6kvitwFUwkfsG9vXOF1nUJugg-g3Iy9myxX4kdCMx-ugXbflbIgVSJtjJix4sikRz0en0Hvi3Lbo7e9-u87X7OH9KpUiRb6DTvrd3t4i6lMX53HEgC2X9YC26Uy59GZ_wIQ0flM |
link.rule.ids | 230,315,733,786,790,870,891,2115,24346,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKkaAX3qjL00ickLKbOLZjH0uhWqBbrVCLerMcewIr2KTaZBHqr8eTB9pwg2ucyHFmnJlv_PkzIa8hxFGAgkc-0T7iVuhI28RFGngBWYhRqmhZvmdyfsE_XorLPSKGvTAtad_lq2n5Yz0tV99abuXV2s0GnthsuTjWnHGp9OwGuRnmKxM7IL39AQfMEFBEt4YZIJieFVB63OnH2BTFWDSe_5aGRD5JkUq3E5Ba3f5RsjmmSu7EnpO75Mvw1h3l5Pt02-RTd_2XoOM_D-seudNno_Soa75P9qB8QG4t-vX2h-S6EzeuaVXQ5fLo8zsa_A3ozwCwkT9Dq5KGBJLubOKim450CzVtKgq_AKuNHuiqpMjahBpoL-VaU6wBU6wBU0aHGjBdo0Jos60fkYuT9-fH86g_rSFynLMmSgVPklwE-KdUanOlrIytkjnogmeFl8CkcEwX4DnX1nqZax0QskcEg1lo-pjsl1UJh4RmLCRxLI9Daqp5DsImqCmkY89VQKixn5A3g8nMVSfKYQKYQVOb1tQGTW06U0_IWzTqnxtRT7u9UG2-mv7zm9hlmbBe5YnzoW-nbOZkEYNQ3nngdkJeDS5hwvzDRRVbQrWtDctQ8EgqlUxINvKVUY_jluABrZJ3b_En__3kS3J7fr44Nacfzj49JQc4bCx4J_IZ2W82W3geMqYmf9HOj9-n-Bib |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bi9QwFA66wuKLd3G8RvBJ6C1N0-Rx3XVYL7sM4sLiS0iTUx102mHaEdlfb04v0vq4r21KWr6T5nwnX74Q8gb8PApQ8sAlygXcZCpQJrGBAl5C7ucoWXYq33NxesE_XmaXk6O-OtG-LdZh9WsTVusfnbZyu7HRqBOLVmfHijMupIq2roxuklt-zLJ8QtS7n7DnDZ5J9OuYnoapqITK4W4_xkI0ZFF4Blzqk_kkRTndZFLqvPtnCedcLjmZf5Z3ybfxzXvZyc9w3xahvfrP1PFan3aP3BmyUnrUN7lPbkD1gByeDevuD8lVb3Lc0Lqkq9XRlxPq4w7ob0-0UUdD64r6RJJONnPRXS--hYa2NYU_gFVHB3RdUVRvQgN0sHRtKNaCKdaCKaNjLZhu0Cm03TePyMXy_dfj02A4tSGwnLM2SDOeJEXmaaCUqSmkNCI2UhSgSp6XTgATmWWqBMe5MsaJQinPlB0yGcxG08fkoKoreEJoznwyx4rYp6iKF5CZBL2FVOy49Ew1dgvydoRNb3tzDu1JDcKtO7g1wq17uBfkHQL7ryH6ancX6t13PUCgY5vnmXGySKzzfVtpcivKGDLprANuFuT1GBbaj0NcXDEV1PtGsxyNj4SUyYLks3iZ9Ti_46Ogc_QeUH967SdfkcPVyVJ__nD-6Rm5jV-Nde9EPCcH7W4PL3zi1BYvuyHyF2AdGxs |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effects+of+PPARD+gene+variants+on+the+therapeutic+responses+to+exenatide+in+chinese+patients+with+type+2+diabetes+mellitus&rft.jtitle=Frontiers+in+endocrinology+%28Lausanne%29&rft.au=Song%2C+Jinfang&rft.au=Li%2C+Na&rft.au=Hu%2C+Ruonan&rft.au=Yu%2C+Yanan&rft.date=2022-08-16&rft.issn=1664-2392&rft.eissn=1664-2392&rft.volume=13&rft.spage=949990&rft.epage=949990&rft_id=info:doi/10.3389%2Ffendo.2022.949990&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1664-2392&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1664-2392&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1664-2392&client=summon |